Biology Reference
In-Depth Information
Oostendorp RA, Ott I (2010) Local erythro-
poietin and endothelial progenitor cells
improve regional cardiac function in acute
myocardial infarction. BMC Cardiovasc
Disord 10:43
50. Yano T, Miki T, Tanno M, Kuno A, Itoh T,
Takada A, Sato T, Kouzu H, Shimamoto K,
Miura T (2011) Hypertensive hypertrophied
myocardium is vulnerable to infarction and
refractory to erythropoietin-induced protec-
tion. Hypertension 57:110-115
51. Cheung WK, Goon BL, Guilfoyle MC,
Wacholtz MC (1998) Pharmacokinetics and
pharmacodynamics of recombinant human
erythropoietin after single and multiple subcu-
taneous doses to healthy subjects. Clin
Pharmacol Ther 64(4):412-423
52. Ehrenreich H, Hasselblatt M, Dembowski C,
Cepek L, Lewczuk P, Stiefel M, Rustenbeck
HH, Breiter N, Jacob S, Knerlich F, Bohn M,
Poser W, Rüther E, Kochen M, Gefeller O,
Gleiter C, Wessel TC, De Ryck M, Itri L, Prange
H, Cerami A, Brines M, Sirén AL (2002)
Erythropoietin therapy for acute stroke is both
safe and beneficial. Mol Med 8(8):495-505
53. Tang YD, Hasan F, Giordano FJ, Pfau S,
Rinder HM, Katz SD (2009) Effects of recom-
binant human erythropoietin on platelet acti-
vation in acute myocardial infarction: results of
a double-blind, placebo-controlled, random-
ized trial. Am Heart J 158(6):941-947
54. Lipsic E, van der Meer P, Voors AA,
Westenbrink BD, van den Heuvel AF, de Boer
HC, van Zonneveld AJ, Schoemaker RG, van
Gilst WH, Zijlstra F, van Veldhuisen DJ (2006)
A single bolus of a long-acting erythropoietin
analogue darbepoetin-alfa in patients with
acute myocardial infarction: a randomized fea-
sibility and safety study. Cardiovasc Drugs
Ther 20(2):135-141
55. Liem A, van de Woestijne AP, Bruijns E,
Roeters van Lennep HW, de Boo JA, van
Halteren HK, van Es TP, Jukema JW, van der
Laarse A, Zwinderman AH, van Veldhuisen DJ
(2009) Effect of EPO administration on myo-
cardial infarct size in patients with non-STE
acute coronary syndromes; results from a pilot
study. Int J Cardiol 131(2):285-287, Epub
2007 Nov 1
56. Binbrek AS, Mittal B, Rao KN, Sobel BE (2007)
The potential of erythropoietin for conferring
cardioprotection complementing reperfusion.
Coron Artery Dis 18(7):583-585, Review
57. Binbrek AS, Rao NS, Al Khaja N, Assaqqaf J,
Sobel BE (2009) Erythropoietin to augment
myocardial salvage induced by coronary
thrombolysis in patients with ST segment ele-
vation acute myocardial infarction. Am J
Cardiol 104(8):1035-1040
58. Ozawa T, Toba K, Suzuki H, Kato K, Iso Y,
Akutsu Y, Kobayashi Y, Takeyama Y, Kobayashi
N, Yoshimura N, Akazawa K, Aizawa Y, EPO/
AMI-I Pilot Study Researchers (2010) Single-
dose intravenous administration of recombinant
human erythropoietin is a promising treatment
for patients with acute myocardial infarction—
randomized controlled pilot trial of EPO/
AMI-1 study. Circ J 74(7):1415-1423
59. Yoshimura N, Toba K, Ozawa T, Aizawa Y,
Hosoya T (2010) A novel program to accu-
rately quantify infarction volume by (99 m)Tc
MIBI SPECT, and its application for re-ana-
lyzing the effect of erythropoietin administra-
tion in patients with acute myocardial
infarction. Circ J 74(12):2741-2743
60. Belonje AM, Voors AA, van Gilst WH, Anker
SD, Slart RH, Tio RA, Zijlstra F, van Veldhuisen
DJ, HEBE III investigators (2008) Effects of
erythropoietin after an acute myocardial infarc-
tion: rationale and study design of a prospec-
tive, randomized, clinical trial (HEBE III).
Am Heart J 155(5):817-822
61. Voors AA, Belonje AM, Zijlstra F, Hillege HL,
Anker SD, Slart RH, Tio RA, van't Hof A,
Jukema JW, Peels HO, Henriques JP, Ten Berg
JM, Vos J, van Gilst WH, van Veldhuisen DJ,
HEBE III Investigators (2010) A single dose
of erythropoietin in ST-elevation myocardial
infarction. Eur Heart J 31(21):2593-2600
62. Ott I, Schulz S, Mehilli J, Fichtner S,
Hadamitzky M, Hoppe K, Ibrahim T,
Martinoff S, Massberg S, Laugwitz KL,
Dirschinger J, Schwaiger M, Kastrati A, Schmig
A, REVIVAL-3 Study Investigators (2010)
Erythropoietin in patients with acute
ST-segment elevation myocardial infarction
undergoing primary percutaneous coronary
intervention: a randomized, double-blind trial.
Circ Cardiovasc Interv 3(5):408-413
63. Taniguchi N, Nakamura T, Sawada T, Matsubara
K, Furukawa K, Hadase M, Nakahara Y,
Nakamura T, Matsubara H (2010)
Erythropoietin prevention trial of coronary rest-
enosis and cardiac remodeling after ST-elevated
acute myocardial infarction (EPOC-AMI): a
pilot, randomized, placebo-controlled study.
Circ J 74(11):2365-2371
64. Melloni C, Rao SV, Povsic TJ, Melton L, Kim
RJ, Kilaru R, Patel MR, Talan M, Ferrucci L,
Longo DL, Lakatta EG, Najjar SS, Harrington
RA (2010) Design and rationale of the reduc-
tion of infarct expansion and ventricular
remodeling with erythropoietin after large
myocardial infarction (REVEAL) trial. Am
Heart J 160(5):795-803, e2
65. Najjar SS, Rao SV, Melloni C, Raman SV,
Povsic TJ, Melton L, Barsness GW, Prather K,
Heitner JF, Kilaru R, Gruberg L, Hasselblad
V, Greenbaum AB, Patel M, Kim RJ, Talan M,
Ferrucci L, Longo DL, Lakatta EG, Harrington
RA, REVEAL Investigators (2011) Intravenous
erythropoietin in patients with ST-segment
Search WWH ::
Custom Search